ClariTrial — AI Clinical Trial Intelligence

Explore/systemic lupus erythematosus SLE autoimmune IRF5 interferon

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

521 results for “systemic lupus erythematosus SLE autoimmune IRF5 interferon” · Phase 2 · Phase 1

Page 1 of 35

↩No exact matches for “systemic lupus erythematosus SLE autoimmune IRF5 interferon”. Showing results for “systemic lupus erythematosus SLE autoimmune” instead.

Recruiting

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Phase 1Autoimmune DiseaseCrohn DiseaseDermatomyositis

Biospecimen CollectionNivolumab

National Cancer Institute (NCI)300 participants52 sites · United States, CanadaCompletes Mar 2028

CT.gov Full analysis →

Completed

Results posted

Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients

Phase 1Systemic Lupus Erythematosus

Gardasil

Wayne State University37 participants1 site · United StatesCompletes Jan 2015

CT.gov Full analysis →

Recruiting

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Phase 1Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren's Syndrome (SS)

YTS109 cell

China Immunotech (Beijing) Biotechnology Co., Ltd.18 participants1 site · ChinaCompletes Aug 2026

CT.gov Full analysis →

Recruiting

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Phase 2Lupus Nephritis

Iptacopan (part 1)Iptacopan (part 2)Placebo + standard of care+1 more

Novartis Pharmaceuticals240 participants103 sites · United States, Argentina, BrazilCompletes Mar 2026

CT.gov Full analysis →

Completed

Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)

Phase 1Phase 2Lupus Erythematosus, SystemicLupus Nephritis

CTLA4-IgG4m (RG2077)Cyclophosphamide

National Institute of Allergy and Infectious Diseases (NIAID)6 participants2 sites · United StatesCompletes Jan 2006

CT.gov Full analysis →

UNKNOWN

Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis

Phase 1Phase 2Autoimmune Hepatitis

conventional plus UC-MSC treatmentConventional plus placebo treatment

Beijing 302 Hospital100 participants1 site · ChinaCompletes Oct 2014

CT.gov Full analysis →

UNKNOWN

Mesenchymal Stromal Cells (MSC´s) in Renal Lupus

Phase 2Lupus Erythematosus, SystemicLupus Glomerulonephritis

MSC treatmentStandard of CarePlacebo

Universidad de los Andes, Chile39 participants2 sites · ChileCompletes Dec 2024

CT.gov Full analysis →

Completed

Results posted

Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects

Phase 1Systemic Lupus Erythematosus

Belimumab for IVBelimumab for SC

GlaxoSmithKline36 participants1 site · ChinaCompletes Jan 2020

CT.gov Full analysis →

Not Yet Recruiting

F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus

Phase 1Lupus Erythematosis

After preconditioning with chemotherapy, F01 will be evaluated.

Shanghai Simnova Biotechnology Co.,Ltd.50 participants1 site · ChinaCompletes Jan 2027

CT.gov Full analysis →

Completed

Results posted

A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

Phase 1Phase 2Lupus NephritisSystemic Lupus Erythematosus

KZR-616

Kezar Life Sciences, Inc.69 participants36 sites · United States, Australia, ColombiaCompletes Aug 2022

CT.gov Full analysis →

Active

A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus

Phase 1Systemic Lupus ErythematosusSLE (Systemic Lupus)Autoimmune

CUG252Placebo

Cugene Inc.40 participants11 sites · United StatesCompletes Apr 2025

CT.gov Full analysis →

Recruiting

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Phase 1Systemic Lupus ErythematosusLupus Nephritis (LN)Sjogren's Syndrome

YTS109 cell

China Immunotech (Beijing) Biotechnology Co., Ltd.18 participants1 site · ChinaCompletes Nov 2026

CT.gov Full analysis →

Recruiting

Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells

Phase 2Lupus NephritisLupus Erythematosus

Mesenchymal stem cells (MSC)Placebo

Red de Terapia Celular20 participants1 site · SpainCompletes Dec 2026

CT.gov Full analysis →

Terminated

Results posted

A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

Phase 2Lupus Nephritis

zetomipzomibplacebo

Kezar Life Sciences, Inc.84 participants50 sites · United States, Argentina, BrazilCompletes Nov 2024

CT.gov Full analysis →

Terminated

An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

Phase 1InflammationSystemic Lupus Erythematosus

NNC0114-0006placebo

Novo Nordisk A/S10 participants5 sites · United States, Hungary, PolandCompletes Feb 2014

CT.gov Full analysis →

1–15 of 521

Explore/systemic lupus erythematosus SLE autoimmune IRF5 interferon

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

521 results for “systemic lupus erythematosus SLE autoimmune IRF5 interferon” · Phase 2 · Phase 1

Page 1 of 35

↩No exact matches for “systemic lupus erythematosus SLE autoimmune IRF5 interferon”. Showing results for “systemic lupus erythematosus SLE autoimmune” instead.

Recruiting

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Phase 1Autoimmune DiseaseCrohn DiseaseDermatomyositis

Biospecimen CollectionNivolumab

National Cancer Institute (NCI)300 participants52 sites · United States, CanadaCompletes Mar 2028

CT.gov Full analysis →

Completed

Results posted

Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients

Phase 1Systemic Lupus Erythematosus

Gardasil

Wayne State University37 participants1 site · United StatesCompletes Jan 2015

CT.gov Full analysis →

Recruiting

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Phase 1Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren's Syndrome (SS)

YTS109 cell

China Immunotech (Beijing) Biotechnology Co., Ltd.18 participants1 site · ChinaCompletes Aug 2026

CT.gov Full analysis →

Recruiting

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Phase 2Lupus Nephritis

Iptacopan (part 1)Iptacopan (part 2)Placebo + standard of care+1 more

Novartis Pharmaceuticals240 participants103 sites · United States, Argentina, BrazilCompletes Mar 2026

CT.gov Full analysis →

Completed

Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)

Phase 1Phase 2Lupus Erythematosus, SystemicLupus Nephritis

CTLA4-IgG4m (RG2077)Cyclophosphamide

National Institute of Allergy and Infectious Diseases (NIAID)6 participants2 sites · United StatesCompletes Jan 2006

CT.gov Full analysis →

UNKNOWN

Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis

Phase 1Phase 2Autoimmune Hepatitis

conventional plus UC-MSC treatmentConventional plus placebo treatment

Beijing 302 Hospital100 participants1 site · ChinaCompletes Oct 2014

CT.gov Full analysis →

UNKNOWN

Mesenchymal Stromal Cells (MSC´s) in Renal Lupus

Phase 2Lupus Erythematosus, SystemicLupus Glomerulonephritis

MSC treatmentStandard of CarePlacebo

Universidad de los Andes, Chile39 participants2 sites · ChileCompletes Dec 2024

CT.gov Full analysis →

Completed

Results posted

Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects

Phase 1Systemic Lupus Erythematosus

Belimumab for IVBelimumab for SC

GlaxoSmithKline36 participants1 site · ChinaCompletes Jan 2020

CT.gov Full analysis →

Not Yet Recruiting

F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus

Phase 1Lupus Erythematosis

After preconditioning with chemotherapy, F01 will be evaluated.

Shanghai Simnova Biotechnology Co.,Ltd.50 participants1 site · ChinaCompletes Jan 2027

CT.gov Full analysis →

Completed

Results posted

A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

Phase 1Phase 2Lupus NephritisSystemic Lupus Erythematosus

KZR-616

Kezar Life Sciences, Inc.69 participants36 sites · United States, Australia, ColombiaCompletes Aug 2022

CT.gov Full analysis →

Active

A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus

Phase 1Systemic Lupus ErythematosusSLE (Systemic Lupus)Autoimmune

CUG252Placebo

Cugene Inc.40 participants11 sites · United StatesCompletes Apr 2025

CT.gov Full analysis →

Recruiting

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Phase 1Systemic Lupus ErythematosusLupus Nephritis (LN)Sjogren's Syndrome

YTS109 cell

China Immunotech (Beijing) Biotechnology Co., Ltd.18 participants1 site · ChinaCompletes Nov 2026

CT.gov Full analysis →

Recruiting

Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells

Phase 2Lupus NephritisLupus Erythematosus

Mesenchymal stem cells (MSC)Placebo

Red de Terapia Celular20 participants1 site · SpainCompletes Dec 2026

CT.gov Full analysis →

Terminated

Results posted

A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

Phase 2Lupus Nephritis

zetomipzomibplacebo

Kezar Life Sciences, Inc.84 participants50 sites · United States, Argentina, BrazilCompletes Nov 2024

CT.gov Full analysis →

Terminated

An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

Phase 1InflammationSystemic Lupus Erythematosus

NNC0114-0006placebo

Novo Nordisk A/S10 participants5 sites · United States, Hungary, PolandCompletes Feb 2014

CT.gov Full analysis →

1–15 of 521